Stifel analyst Paul Matteis raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $133.00 (from $131.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE